News

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...
A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...
Dr. Mahsa Tehrani discusses how patients use medication to help them lose weight on 'America Reports.' ...
Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...
Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...